SCHEMBL155141

SCHEMBL155141

B(Oc1ccoc1)Oc1ccoc1

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP1B1 Q16678 1/20 0.31
MMP2 P08253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14002603 0.80
SCHEMBL5135507 0.75 MMP2 (0.35) CYP1A1CYP1A2CYP1B1MMP2
SCHEMBL16993776 0.70
SCHEMBL515092 0.70
SCHEMBL1145575 0.70
SCHEMBL23829792 0.65 ACLY (0.34) CYP1A1CYP1A2CYP1B1
SCHEMBL24843796 0.65
SCHEMBL21965726 0.65 CYP1A1 (0.33) CYP1A1CYP1A2CYP1B1
SCHEMBL7770920 0.65
SCHEMBL14876788 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751364-A Dimethoxy quinazoline compound and application thereof 中日友好医院(中日友好临床医学研究所) 2025-04-04 CN claimed
US-20210403449-A1 BIPHENYL DIARYL PYRIMIDINE DERIVATIVE WITH AROMATIC HETEROCYCLIC STRUCTURE FUDAN UNIVERSITY (CN) 2021-12-30 US claimed
US-12522813-B2 Mannanase for formulations having pH 5-12 BASF SE (DE) 2026-01-13 US disclosed
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-07-31 US disclosed
CN-120118071-A Quinazoline compound and application thereof 北京化工大学 2025-06-10 CN disclosed
CN-119751364-A Dimethoxy quinazoline compound and application thereof 中日友好医院(中日友好临床医学研究所) 2025-04-04 CN disclosed
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-08-29 US disclosed
US-20240132808-A1 Storage-Stable Hydrolase Containing Liquids BASF SE (DE) 2024-04-25 US disclosed
US-11912685-B2 Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure FUDAN UNIVERSITY (CN) 2024-02-27 US disclosed
EP-4301752-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2024-01-10 EP disclosed
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-01-09 US disclosed
US-20040106559-A1 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-03 US disclosed
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-05-06 US disclosed
US-20040063674-A1 Tetracycline compounds having target therapeutic activities PARATEK PHARMACEUTICALS, INC. 2004-04-01 US disclosed
EP-1381372-A2 SUBSTITUTED TETRACYCLINE COMPOUNDS AS SYNERGISTIC ANTIFUNGAL AGENTS Paratek Pharmaceuticals, Inc. (US) 2004-01-21 EP disclosed
WO-2003099274-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO disclosed
WO-2003082272-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS CHIRON CORPORATION (US) 2003-10-09 WO disclosed
WO-2003079984-A2 SUBSTITUTED TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. (US) 2003-10-02 WO disclosed
US-20030166585-A1 Substituted tetracycline compounds as synergistic antifungal agents PARATEK PHARMACEUTICALS, INC. 2003-09-04 US disclosed
WO-2002072031-A2 SUBSTITUTED TETRACYCLINE COMPOUNDS AS SYNERGISTIC ANTIFUNGAL AGENTS PARATEK PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166585-A1 Substituted tetracycline compounds as synergistic antifungal agents TUBB6, ETF1, TUBB2A CYP1A1 2886/4885CYP1A2 1917/4885CYP1B1 3290/4885
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF CYP1A1 1128/4885CYP1A2 1518/4885CYP1B1 691/4885
US-11912685-B2 Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure DPYD, TYMP, DHODH CYP1A1 262/4885CYP1A2 212/4885CYP1B1 174/4885
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF TRIB2, YAP1, IDO2 CYP1A1 1547/4885CYP1A2 273/4885CYP1B1 1009/4885
US-20040063674-A1 Tetracycline compounds having target therapeutic activities TBCA, TUBB6, TUBB CYP1A1 3389/4885CYP1A2 2912/4885CYP1B1 3921/4885
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof ABCB11, CEL, NDC1 CYP1A1 320/4885CYP1A2 115/4885CYP1B1 210/4885
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 CYP1A1 1786/4885CYP1A2 2017/4885CYP1B1 1817/4885
US-20040106559-A1 Hepatitis C virus inhibitors HAVCR2, HCCS, RNASE1 CYP1A1 121/4885CYP1A2 138/4885CYP1B1 33/4885
US-20210403449-A1 BIPHENYL DIARYL PYRIMIDINE DERIVATIVE WITH AROMATIC HETEROCYCLIC STRUCTURE DPYD, TYMP, DHODH CYP1A1 262/4885CYP1A2 212/4885CYP1B1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.